Your first 90 days
Your first 90 days with Firazyr for hereditary angioedema (HAE) attacks
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Firazyr is not taken on a schedule. It sits in its carton until an HAE attack starts, so the first 90 days are about being ready. That means an insurance approval, syringes at home, injection training and knowing what the label says about repeat doses and throat attacks. This page lays that out from the FDA label, Takeda's own Firazyr pages and one insurer's written rules.
What has to happen before the first bottle ships
Firazyr has no REMS, so the first syringes wait on a prescription, a prior authorization, a pharmacy delivery and injection training. These are the 6 things in the way, in order.
A prescription and a Start Form
Takeda's prescriber page says the office can enroll you in Takeda Patient Support online or by faxing a completed Firazyr Start Form.
- The program then checks your insurance benefits.Takeda prescriber page
The insurance approval
Cigna requires prior authorization for icatibant.
- Its policy asks for lab results showing low C1 inhibitor function and low C4, plus an allergist, immunologist or HAE specialist.Cigna policy
Brand or generic
Cigna's policy covers brand Firazyr, generic icatibant and Sajazir, another icatibant brand.
- It treats brand Firazyr as non-preferred and asks for a trial of generic icatibant first.Cigna policy
Injection training
The label says you may inject Firazyr yourself after training under the guidance of a healthcare professional.
- Takeda Patient Support can arrange in-home injection training from a specially trained nurse.Takeda Firazyr page
A plan for throat attacks
The label asks prescribers to advise patients about attacks of the throat, called laryngeal attacks.
- Its patient leaflet says to inject Firazyr and then go to the nearest hospital emergency room right away.FDA label
A medicine list for your care team
The Patient Information asks you to tell your provider about every medicine, vitamin and herbal supplement.
- The label says Firazyr may weaken the effect of ACE inhibitor blood pressure medicines.FDA label
The days that matter
Counted from the day the first syringes arrive, because Firazyr is used only when an attack starts and has no dosing calendar. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form, then the benefits check
The office enrolls you online or by fax, and Takeda Patient Support looks into your insurance benefits.
- No source sets how long an approval takes.
The pharmacy and injection training
Takeda Patient Support works with your specialty pharmacy to get the medicine to you.
- It can also arrange in-home injection training from a specially trained nurse.
Syringes in hand
Each carton holds one single-dose prefilled syringe and one needle.
- The label says to store it between 36°F and 77°F (2°C to 25°C), in the carton, and never frozen.
When an attack starts
The dose at an attack
The label dose is one 30mg syringe, injected under the skin of the belly over at least 30 seconds.
- If symptoms continue or come back, the label allows another dose at least 6 hours later, up to 3 doses in 24 hours.
After any use
Replacing a used syringe
Each syringe is single-dose, so every injection uses up one carton.
- Takeda's Firazyr page encourages people with HAE to keep enough for 2 attacks, or at least 2 doses, on hand.
Three months in
Firazyr has no dosing schedule, so unused cartons stay stored until an attack.
- The Patient Information says to read the leaflet again with each refill, because it may have new information.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Firazyr label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated July 7, 2025, read from the FDA's label database today. FDA label
- June 2025
The prescribing information, Patient Information and Instructions for Use all carry a June 2025 revision date. This label lists no recent major changes.FDA label
- January 2024
The FDA approved changes to the patient leaflet and the injection instructions to reflect a replacement needle.FDA letter
- April 2020
The FDA approved a rewritten pregnancy and breastfeeding section in its current format. The same action added hives to the side effects reported since approval.FDA letter
- November 2015
The label gained results from a required 2-year cancer study in mice. The current label says no evidence of tumors was seen in mice or rats.FDA letter
- August 2013
The label gained results from a required 2-year cancer study in rats.FDA letter
- August 2011
The FDA first approved Firazyr on August 25th to treat acute HAE attacks in adults 18 and older.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The dose
The label dose is 30mg, which is one full prefilled syringe of 3mL.
- It is injected under the skin of the belly area.FDA label
- Repeat doses and the daily limit
If symptoms continue or come back, the Patient Information says you may repeat the injection at least six hours apart.
- It says not to use more than 3 doses in 24 hours.FDA label
- Throat attacks
The label warns that a laryngeal attack can block the airway.
- Its patient leaflet says to inject Firazyr and then go to the nearest hospital emergency room right away.FDA label
- When it is used
The label says patients may self-administer Firazyr upon recognition of symptoms of an HAE attack, after training.
- Your healthcare provider tells you when to use it.FDA label
- Who gives the shot
The Patient Information says your healthcare provider will teach you or a caregiver how to give Firazyr injections.
- Firazyr is approved for adults 18 and older only.FDA label
- Where the shot goes
The instructions describe a fold of skin on the stomach, about 2 to 4 inches (5 to 10cm) below the belly button on either side.
- They say to stay at least 2 inches (5cm) from scars and to avoid bruised, swollen or painful skin.FDA label
- Checking and injecting
The Instructions for Use say the medicine should be clear and colorless, with no particles.
- The label says to attach the needle provided and not to use a different one.
- The plunger is pushed for at least 30 seconds, until the syringe is empty.FDA label
- Storage
The Patient Information says to store Firazyr between 36°F and 77°F (2°C to 25°C), in the original carton, and not to freeze it.
- It also says to keep Firazyr out of the reach of children.FDA label
- Expiry dates
The label's storage section gives a temperature range but does not state a shelf life.
- Your pharmacist can tell you the expiration date on each carton they send.FDA label
- Driving after a dose
Tiredness, drowsiness and dizziness can happen after Firazyr.
- If they do, the Patient Information says not to drive, use machinery or do anything that needs you to be alert.FDA label
- Needles and sharps
The Instructions for Use say to put the used syringe, with the needle attached, in an FDA-cleared sharps container right away.
- They also describe a heavy-duty plastic household container with a tight, puncture-resistant lid.FDA label
- Pregnancy and breastfeeding
The Patient Information says it is not known if Firazyr will harm an unborn baby or passes into breast milk.
- The label says available data in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other harm to mother or baby.FDA label
- Generic icatibant
The Firazyr label covers Takeda's brand and does not discuss generics.
- FDA's drug database lists 8 generic icatibant injections as therapeutic equivalents.
- Your prescriber and plan decide which one you receive.Drugs@FDA
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
An attack of the throat
Laryngeal attacks can block the airway.
- The Patient Information says that if you have a laryngeal attack, inject Firazyr and then go to the nearest hospital emergency room right away.FDA label
Reactions where the shot went in
Redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure or pain at the injection site.
- In the placebo-controlled trials these occurred in 97% of people on Firazyr against 33% on placebo.FDA label
Other common side effects
Fever, too much of an enzyme called transaminase in the blood, dizziness, nausea, headache and rash.
- The Patient Information says to tell your provider about any side effect that bothers you or does not go away.FDA label
Tiredness, drowsiness or dizziness
These have been reported after Firazyr.
- If they happen, the Patient Information says not to drive a car, use machinery or do anything that needs you to be alert.FDA label
Symptoms that continue or come back
The label allows a repeat dose at least 6 hours later, up to 3 doses in 24 hours.
- In an analysis of the first 5 treated attacks in the trials, 93% were treated with a single dose.
- Your allergist decides what a slow response means for your plan.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedCigna asks for a functional C1 inhibitor level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist. The office sends both lab reports.Cigna policy
- The plan wants generic icatibant, not brand FirazyrCigna lists Firazyr as non-preferred. Its policy asks that the patient tried generic icatibant and cannot continue because of an inactive ingredient difference. The prescriber must document that it would cause a significant allergy or serious adverse reaction.Cigna policy
- HAE with normal C1 inhibitorCigna covers icatibant for this type under separate criteria. They include normal C1 inhibitor and C4 results, attacks that did not respond to high-dose antihistamines, and a confirmed gene variant or a family history.Cigna policy
- A request to use it for preventionCigna does not cover icatibant to prevent attacks, and says it is not indicated for that use. The Firazyr label approves it only to treat acute attacks.Cigna policy
- A dose the plan will not coverCigna approves up to 30mg per injection, no more often than three times daily. Other doses go to case-by-case review by a Cigna clinician.Cigna policy
- A renewal after the first yearCigna approves icatibant for 1 year at a time. For renewal, the prescriber confirms a favorable response, such as shorter attacks, quick symptom relief or complete resolution of symptoms.Cigna policy
- A copay you cannot payWith commercial insurance, the Takeda co-pay program can cover up to 100% of out-of-pocket co-pay costs, up to a yearly maximum. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Takeda says it may connect people who cannot afford treatment to other programs.Takeda Firazyr page
- The plan uses a co-pay maximizerTakeda says it may lower or end co-pay help for people in a plan with a co-pay maximizer program. Its terms ask you to notify the program right away if you learn your plan uses one.Takeda Firazyr page
Cigna prior authorization policy, January 1, 2026
- HAE type I or type II, with a functional C1 inhibitor level under 50% of normal at baseline, with lab documentation
- A serum C4 level below normal at baseline, with lab documentation
- HAE with normal C1 inhibitor is covered under separate criteria, including normal lab results, no response to high-dose antihistamines, and a gene variant or family history
- Prescribed by or in consultation with an allergist, immunologist or a physician who specializes in HAE
- Brand Firazyr is non-preferred and needs a documented trial of generic icatibant that could not continue because of an inactive ingredient difference
- Up to 30mg per injection, no more often than three times daily
- Not covered to prevent HAE attacks
Approval length. Approved a year at a time. Renewal asks for the documented diagnosis and a favorable response to icatibant, according to the prescriber.
This version took effect January 1, 2026. It cites the October 2021 Firazyr prescribing information, which predates the June 2025 label. The policy covers brand Firazyr, generic icatibant and Sajazir. Its 2026 update removed a rule against using icatibant with other attack medicines. Other plans set their own criteria. It is here as an example, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- Support specialists who answer questions and help with the health insurance process
- The Takeda Patient Support Co-Pay Assistance Program for commercial insurance, including Marketplace plans, covering up to 100% of out-of-pocket co-pay costs up to a yearly maximum
- No co-pay help for Medicare, Medicare Advantage, Medicaid, TRICARE, VA or other federal or state plans
- Work with your specialty pharmacy or site of care to get your prescribed treatment to you
- In-home injection training from a specially trained nurse
- Directions to community support resources and education
- Possible help in another language if English is not your preferred language
- For the office, a benefits investigation and enrollment online or by faxed Start Form Takeda prescriber page
Details as the drugmaker publishes them. Takeda Firazyr page
Five questions for the pharmacist or the support line
- Are you sending brand Firazyr or generic icatibant, and does it match my prescription?
- How many syringes come in each fill, single cartons or the pack of 3?
- What expiration date is on the cartons you are sending?
- How fast can you replace a syringe after I use one?
- Where can I get a sharps container for used syringes?
Questions people ask in the first weeks
What is the Firazyr dose for an HAE attack?
The label dose is 30mg, one prefilled syringe, injected under the skin of the belly. If symptoms continue or come back, the label allows another dose at least 6 hours later. The label says no more than 3 doses in 24 hours.
What does the label say about throat attacks?
The label warns that laryngeal attacks can block the airway. Its patient leaflet says to inject Firazyr and then go to the nearest hospital emergency room right away.
Can I inject Firazyr myself?
Yes, the label says patients may inject it themselves once they recognize an attack, after training under a healthcare professional's guidance. Takeda Patient Support can arrange in-home injection training.
Does Firazyr need to be refrigerated?
No, the label says to store it between 36°F and 77°F (2°C to 25°C), in the original carton. It must not be frozen.
Is there a generic for Firazyr?
Yes, FDA's drug database lists 8 generic icatibant injections as therapeutic equivalents of Firazyr. Cigna's policy treats brand Firazyr as non-preferred and asks for generic icatibant first. Your prescriber and plan decide which you receive.
Does Medicare work with the Firazyr co-pay program?
No, the Takeda co-pay program excludes Medicare, Medicare Advantage, Medicaid, TRICARE, VA and other government plans. Takeda says it may connect people who cannot afford treatment with other programs.
Free email alert
Hear when the Firazyr label changes
One email the day the FDA revises the Firazyr label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Firazyr only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Hereditary angioedema (HAE) for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - FIRAZYR- icatibant acetate injection, solution (prescribing information revised 6/2025, Patient Information and Instructions for Use revised June 2025), Takeda Pharmaceuticals America, Inc., via DailyMed, July 7, 2025.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 11, 2026.
- FIRAZYR® (icatibant injection) | Information for Patients, Takeda, November 11, 2026.
- FIRAZYR® (icatibant injection) | Clinical Information for Healthcare Professionals, Takeda, November 11, 2026.
- Hereditary Angioedema - Icatibant, Drug Coverage Policy IP0335, Cigna, January 1, 2026.
- Drugs@FDA: FDA-Approved Drugs, New Drug Application (NDA) 022150, FIRAZYR, FDA, November 11, 2026.
- NDA 22150/S-016 supplement approval letter, patient labeling and instructions for use, replacement needle, FDA, January 19, 2024.
- NDA 22150/S-012 and S-013 supplement approval letter, Pregnancy and Lactation Labeling Rule update and postmarketing urticaria, FDA, April 16, 2020.
- NDA 22150/S-007 supplement approval letter, mouse carcinogenicity study results in Section 13.1, FDA, November 24, 2015.
- NDA 22150/S-004 supplement approval letter, rat carcinogenicity study results in Section 13.1, FDA, August 30, 2013.
- NDA 022150 approval letter, Firazyr (icatibant acetate) Injection, FDA, August 25, 2011.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing allergist or immunologist. Found an error? Use the report link in the footer and it will be checked against the source.